Eyestem Secures $10 Million in Funding to Advance RPE Cell Therapy Program

Eyestem获得1000万美元融资以推进RPE细胞治疗项目

August 18, 2025

2025年8月18日

Eyestem Research Pvt. Ltd. has successfully closed a $10 million (USD) funding round, marking a pivotal step in its growth trajectory. The funding was led by a strategic partner and saw strong participation from the company’s existing investors.

Eyestem Research Pvt. Ltd. 成功完成了 1000 万美元的融资回合，标志着其成长历程中的关键一步。本轮融资由一家战略合作伙伴领投，并得到了公司现有投资者的积极参与。

Strategic Investment to Support Global Expansion

战略性投资以支持全球扩张

Speaking about the development, Jogin Desai, Founder and CEO of Eyestem, stated, “This milestone strengthens our foundation for global expansion while ensuring patient access to transformative therapies.” The infusion of capital is expected to drive Eyestem’s clinical development and international reach in the field of regenerative ophthalmology..

关于此次发展，Eyestem创始人兼首席执行官Jogin Desai表示：“这一里程碑巩固了我们全球扩展的基础，同时确保患者能够获得变革性的治疗。”这笔资金的注入有望推动Eyestem在再生眼科领域的临床开发和国际影响力。

Endiya Partners Reaffirms Support for Indian Innovation

恩迪亚合伙人重申对印度创新的支持

Endiya Partners, one of the early backers of Eyestem, underscored the company’s advancement from early-stage laboratory research to late-stage human trials. They highlighted Eyestem as a prime example of how Indian biotechnology can contribute meaningfully to solving global health challenges.

Endiya Partners是Eyestem的早期支持者之一，强调了该公司从早期实验室研究发展到后期人体试验的进展。他们将Eyestem作为一个典型例子，展示了印度生物技术如何为解决全球健康挑战做出有意义的贡献。

Completion of Phase 1 Trial for Eyecyte-RPE

Eyecyte-RPE 第一阶段试验完成

In June 2025, Eyestem announced the completion of its Phase 1 clinical study of Eyecyte-RPE, its investigational retinal pigment epithelium (RPE) cell therapy. The therapy is being developed for patients suffering from geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD)..

2025年6月，Eyestem宣布其研究性视网膜色素上皮（RPE）细胞疗法Eyecyte-RPE的1期临床研究已完成。该疗法正在为因干性年龄相关性黄斑变性（干性AMD）继发的地图样萎缩（GA）患者开发。

The results from this initial phase have been submitted to India’s Central Drugs Standard Control Organisation (CDSCO), the national regulatory body for pharmaceuticals and medical devices. The company is now seeking approval to begin Phase 2 of the study.

该初步阶段的结果已提交给印度中央药品标准控制组织 (CDSCO)，这是印度全国性的药品和医疗器械监管机构。该公司现在正寻求批准以开始第二阶段的研究。

Promising Initial Results and Trial Design

有希望的初步结果和试验设计

The Phase 1 trial was designed to assess both the safety and efficacy of Eyecyte-RPE. Eyestem reported “promising outcomes in the initial phase.” The study involved nine patients across three sequential dose-level (DL) cohorts, receiving escalating doses of:

第一阶段试验旨在评估Eyecyte-RPE的安全性和有效性。Eyestem报告称“初期阶段取得了可喜的成果”。研究涉及九名患者，分为三个连续的剂量水平（DL）组，接受递增剂量：

• 100,000 cells

• 100,000个细胞

• 200,000 cells

• 20万个细胞

• 300,000 cells

• 30万个细胞

Eyecyte-RPE consists of a suspension of human induced pluripotent stem cell (hiPSC)-derived RPE cells, representing a cutting-edge approach to treating retinal degeneration.

Eyecyte-RPE 由人诱导多能干细胞（hiPSC）衍生的视网膜色素上皮（RPE）细胞悬浮液组成，代表了治疗视网膜退化的一种前沿方法。